PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629310
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629310
The Bioresorbable Vascular Scaffold Market size was valued at USD 398.50 Million in 2023, expanding at a CAGR of 8.90% from 2024 to 2032.
The bioresorbable vascular scaffold market focuses on devices designed to treat coronary artery disease by temporarily supporting blood vessels and gradually dissolving over time. These scaffolds, made from biocompatible materials, provide a solution to traditional stents by eventually being absorbed by the body. The growing prevalence of cardiovascular diseases and the demand for less invasive, more efficient treatments are driving the market. Technological advancements in scaffold materials and minimally invasive procedures further contribute to its growth. Despite this, challenges such as high costs and concerns about long-term clinical outcomes compared to traditional metallic stents are hindering widespread adoption. The North American and European markets are dominant, while Asia Pacific is experiencing rapid growth due to better healthcare access and rising awareness.
Bioresorbable Vascular Scaffold Market- Market Dynamics
The increasing prevalence of cardiovascular diseases drives demand for advanced treatments.
The increasing prevalence of cardiovascular diseases (CVD) is a key driver for the bioresorbable vascular scaffold (BVS) market. As the global burden of CVD rises, there is a greater need for advanced treatments like BVS to support coronary artery health. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for an estimated 17.9 million deaths annually, which accounts for 32% of all global deaths. In the United States, the Centers for Disease Control and Prevention (CDC) reports that nearly 18.2 million adults aged 20 and older have coronary artery disease, highlighting the need for innovative solutions such as BVS. As the incidence of CVD continues to rise, the demand for effective, minimally invasive treatments like bioresorbable scaffolds is expected to grow, driving the market forward.
Bioresorbable Vascular Scaffold Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.90% over the forecast period (2024-2032)
Based on Type segmentation, drug-eluting bioresorbable vascular scaffold was predicted to show maximum market share in the year 2023
Based on Material Type segmentation, Polylactic Acid (PLA) was the leading segment in 2023
Based on Application segmentation, Coronary Artery Disease Treatment was the leading segment in 2023
based on region, North America was the leading revenue generator in 2023
The Global Bioresorbable Vascular Scaffold Market is segmented based on Type, Material Type, Application, End-User, and Region.
The market is divided into three categories based on Type: Drug-eluting bioresorbable vascular scaffold, non-drug-eluting bioresorbable vascular scaffold. The drug-eluting bioresorbable vascular scaffold segment is the most prominent in the bioresorbable vascular scaffold (BVS) market. These scaffolds are coated with medications that help prevent restenosis (re-narrowing of the artery) by inhibiting cell growth, making them highly effective in ensuring long-term treatment outcomes. The addition of drug-eluting capabilities significantly reduces the risk of complications, which has made these scaffolds more popular among healthcare providers and patients. As coronary artery disease treatments increasingly focus on minimizing restenosis and improving clinical results, drug-eluting BVSs are gaining preference. Moreover, these scaffolds combine the benefits of both biosorption and drug delivery, providing superior therapeutic efficacy. This segment's growth is further supported by ongoing clinical studies and the successful approval of various drug-eluting BVS products in regions like North America and Europe. Consequently, the drug-eluting segment is expected to remain dominant in the market.
The market is divided into two categories based on Material Type: Polylactic Acid (PLA), Poly-L-lactic Acid (PLLA), Magnesium-Based, and Others. The Polylactic Acid (PLA) segment is the most prominent in the bioresorbable vascular scaffold (BVS) market. PLA is widely used due to its biocompatibility, biodegradability, and mechanical properties that make it an ideal material for vascular scaffolds. It offers the necessary strength and flexibility required to support the artery during the healing process, while also gradually resorbing into the body, reducing long-term complications associated with permanent stents. PLA's established track record in medical applications, including its use in various drug delivery systems, contributes to its significant presence in the BVS market. The segment's growth is driven by the increasing demand for minimally invasive solutions and the advancement of PLA-based scaffold technologies in clinical trials. Given its proven effectiveness and favorable properties, PLA is expected to maintain its dominance in the market.
Bioresorbable Vascular Scaffold Market- Geographical Insights
North America is the leading region in the bioresorbable vascular scaffold (BVS) market, driven by the high incidence of cardiovascular diseases and advanced healthcare infrastructure. The United States holds the largest market share, supported by a strong presence of leading medical device companies such as Abbott Laboratories, Medtronic, and Boston Scientific, which are actively developing and promoting bioresorbable scaffolds. The region benefits from favorable regulatory environments, including the FDA's approval of bioresorbable devices, along with strong healthcare reimbursement policies. Canada also contributes to the growth, with a growing emphasis on innovative cardiovascular treatments. Additionally, extensive research, clinical trials, and early adoption of new technologies by healthcare providers in the U.S. and Canada further fuel market expansion. The increasing demand for minimally invasive procedures and the adoption of advanced stent technologies are expected to maintain North America's dominance in the BVS market.
The competitive landscape of the bioresorbable vascular scaffold (BVS) market is dominated by key players such as Abbott Laboratories, Boston Scientific Corporation, Medtronic, and Biotronik. Abbott is recognized for its Absorb BVS, focusing on high-performance scaffolds and extensive clinical trials. Boston Scientific is advancing bioresorbable scaffold technology, emphasizing improved clinical outcomes. Medtronic continues to innovate with a range of cardiovascular solutions, including BVS, while Biotronik specializes in vascular interventions and invests in clinical studies to enhance device safety and effectiveness. These companies are competing to lead the market by innovating, expanding clinical evidence, and securing regulatory approvals.
In April 2024, the FDA approved Abbott's Esprit BTK, an everolimus-eluting bioresorbable scaffold, for the treatment of patients with below-the-knee (BTK) infra popliteal disease. This approval marks the first-ever device authorized by the FDA specifically for BTK lesions. The decision was based on the positive results from the LIFE-BTK study, which showed reduced risks of amputation, vessel occlusion, revascularization, and restenosis compared to conventional angioplasty.